Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 359

1.

Cyclin D-1, interleukin-6, HER-2/neu, transforming growth factor receptor-II and prediction of relapse in women with early stage, hormone receptor-positive breast cancer treated with tamoxifen.

Muss HB, Bunn JY, Crocker A, Plaut K, Koh J, Heintz N, Rincon M, Weaver DL, Tam D, Beatty B, Kaufman P, Donovan M, Verbel D, Weiss L.

Breast J. 2007 Jul-Aug;13(4):337-45.

PMID:
17593037
2.

[Factors predicting failure of adjuvant hormonotherapy of breast carcinoma. A study in tamoxifen treated patients].

Petráková K, Nenutil R, Grell P, Fabian P, Zichová I, Svoboda M, Palácová M, Vyzula R.

Klin Onkol. 2008;21(5):303-8. Czech.

PMID:
19202962
3.
4.

Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.

Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM.

J Natl Cancer Inst. 2005 Sep 7;97(17):1254-61.

PMID:
16145046
5.

[Association of estrogen and progesterone receptor levels and the expected response to chemotherapy and hormone therapy in breast carcinoma with increased expression of human epidermal growth factor 2].

Susnjar S, Nesković-Konstantinović Z, Stamatović L, Vasović S, Strabic M, Nikolić-Vukosavljević D, Jovanović D.

Srp Arh Celok Lek. 2003 Nov-Dec;131(11-12):443-8. Serbian.

6.

Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.

Kennecke H, McArthur H, Olivotto IA, Speers C, Bajdik C, Chia SK, Ellard S, Norris B, Hayes M, Barnett J, Gelmon KA.

Cancer. 2008 Apr 1;112(7):1437-44. doi: 10.1002/cncr.23320.

7.

Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.

Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J, Houghton J, Williams N, Mallon E, Bishop H, Ellis I, Larsimont D, Sasano H, Carder P, Cussac AL, Knox F, Speirs V, Forbes J, Buzdar A.

J Clin Oncol. 2008 Mar 1;26(7):1059-65. doi: 10.1200/JCO.2007.12.9437. Epub 2008 Jan 28.

PMID:
18227529
8.

An ER activity profile including ER, PR, Bcl-2 and IGF-IR may have potential as selection criterion for letrozole or tamoxifen treatment of patients with advanced breast cancer.

Henriksen KL, Rasmussen BB, Lykkesfeldt AE, Møller S, Ejlertsen B, Mouridsen HT.

Acta Oncol. 2009;48(4):522-31. doi: 10.1080/02841860802676383.

PMID:
19173092
9.

Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients.

Chang J, Powles TJ, Allred DC, Ashley SE, Makris A, Gregory RK, Osborne CK, Dowsett M.

Clin Cancer Res. 2000 Feb;6(2):616-21.

10.

Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer?

Tovey S, Dunne B, Witton CJ, Forsyth A, Cooke TG, Bartlett JM.

Clin Cancer Res. 2005 Jul 1;11(13):4835-42.

11.

Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer.

Esslimani-Sahla M, Simony-Lafontaine J, Kramar A, Lavaill R, Mollevi C, Warner M, Gustafsson JA, Rochefort H.

Clin Cancer Res. 2004 Sep 1;10(17):5769-76.

12.

Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.

Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, Chaudri Ross HA, von Kameke A, Miller WR, Smith I, Eiermann W, Dowsett M.

J Natl Cancer Inst. 2008 Oct 1;100(19):1380-8. doi: 10.1093/jnci/djn309. Epub 2008 Sep 23.

13.

A candidate molecular signature associated with tamoxifen failure in primary breast cancer.

Vendrell JA, Robertson KE, Ravel P, Bray SE, Bajard A, Purdie CA, Nguyen C, Hadad SM, Bieche I, Chabaud S, Bachelot T, Thompson AM, Cohen PA.

Breast Cancer Res. 2008;10(5):R88. doi: 10.1186/bcr2158. Epub 2008 Oct 17.

14.

Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer.

Yamashita H, Yando Y, Nishio M, Zhang Z, Hamaguchi M, Mita K, Kobayashi S, Fujii Y, Iwase H.

Breast Cancer. 2006;13(1):74-83.

15.

A multimarker model to predict outcome in tamoxifen-treated breast cancer patients.

Linke SP, Bremer TM, Herold CD, Sauter G, Diamond C.

Clin Cancer Res. 2006 Feb 15;12(4):1175-83.

16.

Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer.

Hopp TA, Weiss HL, Parra IS, Cui Y, Osborne CK, Fuqua SA.

Clin Cancer Res. 2004 Nov 15;10(22):7490-9.

17.

Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer.

Kenny FS, Hui R, Musgrove EA, Gee JM, Blamey RW, Nicholson RI, Sutherland RL, Robertson JF.

Clin Cancer Res. 1999 Aug;5(8):2069-76.

18.

Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.

Bartlett JM, Ellis IO, Dowsett M, Mallon EA, Cameron DA, Johnston S, Hall E, A'Hern R, Peckitt C, Bliss JM, Johnson L, Barrett-Lee P, Ellis P.

J Clin Oncol. 2007 Oct 1;25(28):4423-30.

PMID:
17906205
19.

HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study.

Arpino G, Green SJ, Allred DC, Lew D, Martino S, Osborne CK, Elledge RM.

Clin Cancer Res. 2004 Sep 1;10(17):5670-6.

20.

Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer.

Foekens JA, Diamandis EP, Yu H, Look MP, Meijer-van Gelder ME, van Putten WL, Klijn JG.

Br J Cancer. 1999 Feb;79(5-6):888-94.

Supplemental Content

Support Center